Dr. Anne W. Beaven
Claim this profileUNC Lineberger Comprehensive Cancer Center
Expert in Lymphoma
Studies Mantle Cell Lymphoma
11 reported clinical trials
25 drugs studied
Area of expertise
1Lymphoma
Global Leadert(11;14) positive
CCND1 positive
CD30 positive
2Mantle Cell Lymphoma
t(11;14) positive
CCND1 positive
Stage I
Affiliated Hospitals
Clinical Trials Anne W. Beaven is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
CD30 CAR T-Cell Therapy
for Lymphoma
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by binding those bacteria or substances, which stops them from growing and causing bad effects. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. Both antibodies and T cells have been used to treat patients with cancers. They both have shown promise, but neither alone has been sufficient to cure most patients. This study is designed to combine both T cells and antibodies to create a more effective treatment called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration. In previous studies, it has been shown that a new gene can be put into T cells that will increase their ability to recognize and kill cancer cells. The new gene that is put in the T cells in this study makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. The purpose of this research study is to establish a safe dose of ATLCAR.CD30 cells to infuse after lymphodepleting chemotherapy and to estimate the number patients whose cancer does not progress for two years after ATLCAR.CD30 administration. This study will also look at other effects of ATLCAR.CD30 cells, including their effect on the patient's cancer.
Recruiting1 award Phase 1 & 231 criteria
More about Anne W. Beaven
Clinical Trial Related3 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Anne W. Beaven has experience with
- Cyclophosphamide
- Rituximab
- Nivolumab
- Bendamustine
- Prednisone
- Zanubrutinib
Breakdown of trials Anne W. Beaven has run
Lymphoma
Mantle Cell Lymphoma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anne W. Beaven specialize in?
Anne W. Beaven focuses on Lymphoma and Mantle Cell Lymphoma. In particular, much of their work with Lymphoma has involved t(11;14) positive patients, or patients who are CCND1 positive.
Is Anne W. Beaven currently recruiting for clinical trials?
Yes, Anne W. Beaven is currently recruiting for 6 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Anne W. Beaven has studied deeply?
Yes, Anne W. Beaven has studied treatments such as Cyclophosphamide, Rituximab, Nivolumab.
What is the best way to schedule an appointment with Anne W. Beaven?
Apply for one of the trials that Anne W. Beaven is conducting.
What is the office address of Anne W. Beaven?
The office of Anne W. Beaven is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.